A Drug Utilization Study of Xofigo Use in Sweden

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/29028
• EU PAS number:
  EUPAS8494
• Study ID:
  29028
• Official title and acronym:
  A Drug Utilization Study of Xofigo Use in Sweden
• DARWIN EU® study:
  No
• Study countries:
  Sweden
• Study status:
  Finalised

Research institution and networks

Institutions

NA

Study timelines

Date when funding contract was signed

Planned: 10/10/2014

Actual: 10/10/2014

Study start date

Planned: 01/05/2015

Actual: 15/04/2015

Date of final study report

Planned: 15/12/2017

Actual: 19/12/2017

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Bayer AG

Study protocol

Initial protocol

Xofigo_DUS_in_Sweden_Study_Protocol_Final_Oct_10_2014

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)